lecozotan and Attention-Deficit-Disorder-with-Hyperactivity

Attention Deficit Hyperactivity Disorder (ADHD) is one of the most common childhood behavioural disorders, the frontline treatments for which are drugs with abuse potential. As a consequence, there is an urgent need to develop non addictive drug treatments with equivalent efficacy. Preclinical evidence suggests that selective serotonin uptake inhibitors (SSRIs) are likely to be effective in ADHD, however clinical reports suggest that SSRIs are of limited therapeutic value for the treatment of ADHD. We propose that this disconnect can be explained by the pattern of drug administration in existing clinical trials (administration for short periods of time, or intermittently) leading to inadequate control of the autoregulatory processes which control 5-HT release, most notably at the level of inhibitory 5-HT

Topics: Animals; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Dioxanes; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Humans; Pindolol; Piperazines; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Receptor, Serotonin, 5-HT1A; Saccades; Selective Serotonin Reuptake Inhibitors; Serotonergic Neurons; Serotonin; Serotonin 5-HT1 Receptor Antagonists; Superior Colliculi